Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Regeneron is now a dividend-paying company. The stock has lagged the market over the last year, and that remains true after the post-earnings rise. Where to invest $1,000 right now? Our analyst ...

Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first starting to issue payouts. Given the strength of its underlying operations ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

In the current session, Regeneron Pharmaceuticals Inc. REGN is trading at $672.39, after a 0.89% decrease. Over the past month, the stock decreased by 0.97%, and in the past year, by 30.36%. With ...

As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year. The company also recently declared a quarterly dividend ...

The figure also surpassed the Zacks Consensus Estimate of $44.96. Regeneron initiated a quarterly cash dividend program and declared a dividend of $0.88 per share. The dividend is payable on March ...